Longevity & AgingAI-Discovered IPF Drug Rentosertib Enters Phase III Trials
Insilico Medicine has launched a Phase III clinical trial for rentosertib, an AI-discovered drug targeting idiopathic pulmonary fibrosis (IPF). IPF is a progressive, fatal lung disease driven by fibrosis, chronic inflammation, and cellular senescence — core hallmarks of biological aging. The drug targets TNIK, a kinase involved in multiple fibrotic pathways, and was identified using Insilico's AI platform by scanning aging-relevant biological networks rather than conventional drug targets. Earlier Phase IIa data from 71 patients showed dose-dependent improvements in lung function. This milestone matters not just as an AI story, but as evidence that aging biology can serve as a practical framework for finding new drug targets in diseases where current medicine falls short.
